Right-to-Try is legislation that allows terminally ill patients to access investigational treatments which have passed Phase I testing through the Food and Drug Administration (FDA), but are not available yet to the public because they have not yet been approved by the FDA. In this informative webinar, Professor Bateman-House, Assistant Professor in the Division of Medical Ethics at New York University Langone Medical Center, discusses the legislation, break down the language, and explain how Right-to-Try can affect cancer patients.